The CCTO provides the infrastructure to support successful cancer clinical research across all departments within the University and supports cancer clinical trials at the U Chicago. It provides oversight and quality control through the implementation of policies and procedures, by centralizing regulatory and reporting functions, supervision of staff, auditing, and tracking of these activities with a centralized database. We are one of only four institutions nationally to be the lead institution for both an NCI Phase 1 cooperative agreement and a Phase 11 Clinical Trials Contract, are members of multiple cooperative groups, and have well established networks of affiliate institutions for both the Phase 11 program and CALGB/Alliance. On average, we have 300-350 therapeutic trials open to accrual per year, and an additional 100-150 open nontherapeutic trials. The office interacts with the Biostatistics Core Facility, the Protocol Review and Monitoring System (PRMS), and the UCCCC Informatics Group. Services provided by the CCTO can be broadly categorized under the following key functions: 1. Regulatory Affairs: Centralized regulatory management (e.g.. Clinical Trials Review Committee (CTRC) /IRB submission;INDs) for all UChicago cancer clinical trials regardless of sponsor, department, study type, or phase. Pediatric Oncology trials operate using a Satellite office, and follow all CCTO policies and procedures. 2. Protocol Tracking and Management: Centralized location and database (Velos eResearch) for tracking protocol-specific data and patient registration;provides web-based direct access (e.g., in clinics) to current protocol documents (e.g., consent forms);and report generation. 3. Affiliate Institution Coordination and Oversight: Infrastructure for the participation of affiliate institutions enrolling patients on trials at the UCCCC, including 7 CALGB/Alliance affiliate institutions,10 Phase 11 NCI contract affiliate institutions, and over 40 additional ad hoc affiliates participating in selected studies within the Disease Programs. 4. Quality Control: Training in clinical research and Velos eResearch;oversight of data and safety monitoring activities;coordination of the audit program;and development and implementation of Standard Operating Procedures (SOPs).

Public Health Relevance

A critical component of the UCCCC's mission is to offer our patients the best and most personalized treatments available. This requires providing access to national cooperative group trials, NCI/CTEP sponsored trials as well as the development of new therapeutic approaches through translational research and the development of investigator-initiated trials. The CCTO is the backbone of these operations and provides services essential to the UCCCC clinical research operation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-39
Application #
8744842
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$192,344
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Zeineddine, Hussein A; Girard, Romuald; Saadat, Laleh et al. (2018) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest :
Kane, Melissa; Deiss, Felicity; Chervonsky, Alexander et al. (2018) A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses. J Virol 92:
Xiao, Annie; Crosby, Jennie; Malin, Martha et al. (2018) Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19:205-213
Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733
Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721
Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4
Pu, Jinyue; Kentala, Kaitlin; Dickinson, Bryan C (2018) Multidimensional Control of Cas9 by Evolved RNA Polymerase-Based Biosensors. ACS Chem Biol 13:431-437
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898

Showing the most recent 10 out of 668 publications